Analyzing Eyepoint Pharmaceuticals (NASDAQ:EYPT) & Astellas Pharma (OTCMKTS:ALPMY)

Astellas Pharma (OTCMKTS:ALPMY) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Volatility & Risk

Astellas Pharma has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Astellas Pharma and Eyepoint Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astellas Pharma	0	3	0	1	2.50
Eyepoint Pharmaceuticals	1	6	4	0	2.27

Eyepoint Pharmaceuticals has a consensus target price of $25.70, suggesting a potential upside of 655.88%. Given Eyepoint Pharmaceuticals’ higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Astellas Pharma.

Profitability

This table compares Astellas Pharma and Eyepoint Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Astellas Pharma	16.01%	25.79%	12.87%
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Insider & Institutional Ownership

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Astellas Pharma and Eyepoint Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astellas Pharma	$14.21 billion	1.83	$1.83 billion	$1.31	10.95
Eyepoint Pharmaceuticals	$2.79 million	105.14	-$231.96 million	($3.74)	-0.91

Astellas Pharma has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Astellas Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Astellas Pharma beats Eyepoint Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Astellas Pharma

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.